9/1/2004

A recent round of venture capital flowed into biotech companies in California's Bay Area. Aerovance, a new venture from Bayer Pharmaceuticals, raised $32 million in funding, while Point Biomedical and AngioScore raised $27.1 million and $15 million, respectively.

Related Summaries